Metabolic peptide research is the busiest corner of the field right now, and it didn't get there by accident. The clinical validation of GLP-1 agonists pulled a wave of research attention into the broader landscape of metabolic signaling — and the compounds under study have moved fast, from single-receptor agents to dual and now triple agonists in the span of a few years. For a cross-category view of the wider catalog, see our Best Research Peptides 2026 guide; for combination protocols, see our Best Research Peptide Stacks guide.
Fat regulation isn't governed by one pathway. It's a layered system of at least three signaling axes relevant to the compounds below: the gut-brain axis (GLP-1, GIP, amylin), the GH-IGF-1 axis (growth hormone-driven lipolysis), and the melanocortin system (central energy-balance regulation in the hypothalamus). Each peptide in this roundup maps to one of those arms, giving researchers a toolkit for studying nearly the whole system. All compounds discussed are sold strictly for in vitro and laboratory research use.
GLP-1 Receptor Research: Semaglutide
Semaglutide is the most extensively published metabolic research peptide in the current literature. GLP-1 receptors sit in the hypothalamus, brainstem, gut, and pancreatic beta cells; when activated, they suppress appetite signaling through the arcuate nucleus, slow gastric emptying, and improve insulin sensitivity in research models. Its research half-life runs approximately seven days, which is why weekly dosing schedules dominate the study protocols using it.
The depth of existing published data makes Semaglutide the natural baseline compound for mechanistic comparison studies. See our Semaglutide research overview and Semaglutide in metabolic research, or view the Semaglutide research compound.
Dual Agonist Research: Tirzepatide
Tirzepatide extends the GLP-1 mechanism by simultaneously engaging GIP receptors, which are expressed in the pancreas, gut, and adipose tissue. In comparative research designs, the dual mechanism consistently produces larger metabolic effects than GLP-1 agonism alone — making Tirzepatide the reference compound for studies isolating what the GIP receptor specifically contributes. Reported research half-life is roughly five days.
See our Tirzepatide in metabolic research article and the head-to-head Semaglutide vs. Tirzepatide comparison, or view the Tirzepatide research compound.
Triple Agonist Research: Retatrutide
Retatrutide adds glucagon receptor agonism on top of Tirzepatide's GLP-1/GIP mechanism — the most significant mechanistic step forward in this class in recent years. Glucagon receptors are dense in the liver, and their activation in research models drives hepatic fat oxidation, giving researchers a third distinct lever alongside appetite (GLP-1) and adipose/insulin signaling (GIP). Published pharmacokinetic data (Jastreboff et al., NEJM 2023) puts its half-life at approximately six days.
For isolating the specific contribution of glucagon receptor activation, Retatrutide paired against Tirzepatide as a control is a clean research design. See our Retatrutide in metabolic research and Retatrutide vs. Tirzepatide comparison, or view the Retatrutide research compound.
Amylin Pathway Research: Cagrilintide
Cagrilintide works through an entirely different receptor system — it's a long-acting amylin analog acting on CALCR/RAMP co-receptor complexes in the brainstem and hypothalamus, rather than GLP-1 receptors. Because the pathway is mechanistically independent of GLP-1, published combination studies with Semaglutide have reported additive effects without receptor competition, which is exactly why it shows up in comparative and combination-focused research designs. Its research half-life runs seven to nine days.
See our Cagrilintide mechanism of action and Cagrilintide vs. Pramlintide comparison, or view the Cagrilintide research compound.
GH Fragment Research: AOD-9604
AOD-9604 approaches metabolism from the growth hormone axis instead of the gut-brain axis. It's a fragment of the hGH sequence (amino acids 176–191) isolated because it appears to retain GH's fat-mobilizing activity without triggering the IGF-1-mediated growth signaling of full-length hGH — letting researchers study the lipolytic arm of GH activity in isolation, primarily through beta-3 adrenergic receptor stimulation in adipocytes.
See our AOD-9604 mechanism of action, or view the AOD-9604 research compound.
Growth Hormone Axis: CJC-1295 & Ipamorelin
The CJC-1295/Ipamorelin pairing is the standard GH-axis research combination. CJC-1295 is a GHRH analog stimulating GH release via GHRH receptors; Ipamorelin is a selective GHSR (ghrelin receptor) agonist driving release through a separate pathway entirely. Combined, research models show GH pulse amplitude well above either compound alone — relevant here because growth hormone directly activates hormone-sensitive lipase, the enzyme that mobilizes stored triglycerides.
See our CJC-1295 & Ipamorelin in growth hormone research, or view the CJC-1295/Ipamorelin blend and CJC-1295 (No DAC) research compounds.
Melanocortin Research: MT-2 & PT-141
MT-2 (Melanotan II) and PT-141 (Bremelanotide) are both melanocortin receptor agonists with relevance to energy-balance research through MC4R activity — a receptor so central to energy homeostasis that MC4R-knockout models reliably develop severe obesity. MT-2 has broad activity across MC1R–MC5R, while PT-141's profile is more focused at MC3R/MC4R, the subtypes most directly tied to energy regulation.
See our Melanotan II mechanism of action and PT-141 mechanism of action, or view the MT-2 and PT-141 research compounds.
Comparison Table
| Peptide | Receptor Target | Primary Studied Mechanism | Research Half-Life |
|---|---|---|---|
| Semaglutide | GLP-1R | Appetite suppression, gastric emptying, insulin sensitivity | ~7 days |
| Tirzepatide | GLP-1R + GIPR | Dual incretin; adipose tissue regulation | ~5 days |
| Retatrutide | GLP-1R + GIPR + GcgR | Triple agonism; hepatic fat oxidation | ~6 days |
| Cagrilintide | CALCR/RAMP | Amylin-pathway satiety; additive with GLP-1 | ~7–9 days |
| AOD-9604 | Beta-3 AR | Lipolysis without IGF-1 activation | Short |
| CJC-1295 + Ipamorelin | GHRHR + GHSR | Amplified GH pulse; GH-driven lipolysis | Varies by form |
FAQ
Why do researchers study multiple metabolic peptides instead of just one? Because each targets a different receptor system. Comparing GLP-1-only agonism (Semaglutide) against dual (Tirzepatide) and triple (Retatrutide) agonism lets researchers isolate exactly what each additional receptor contributes to the observed metabolic outcome.
Why does Cagrilintide get paired with GLP-1 agonists in study designs? Because amylin and GLP-1 receptors are mechanistically independent, so combining them doesn't create receptor competition — it lets researchers test additive effects across two separate pathways.
All compounds referenced are sold for licensed laboratory and in vitro research only, not for human or veterinary use.